Cancer Diagnostic Activity in Canada Before and After COVID-19, 2010–2022

Canadian cancer diagnostic rates for breast, colorectal, cervical, prostate, melanoma, lung, and non-Hodgkin lymphoma from 2010 to 2022. The analysis by Omar Abdel-Rahman reveals a -20.9% drop in colorectal cancer screening for 50–74 year-olds in 2020, with a -8.8% recovery in 2021–2022, indicating non-uniform disruption across diagnostic pathways.

Use Cases

• Modeling the impact of healthcare disruptions on organized screening programs based on breast and colorectal cancer rates.
• Analyzing recovery patterns in opportunistic cancer detection based on prostate cancer and melanoma data.
• Comparing the sensitivity of different diagnostic pathways to external shocks based on the varying disruption observed across cancer types.

Strengths

• Specific drop and recovery rates are provided, such as a -20.9% drop for colorectal cancer screening in 2020.
• Covers a 13-year time series (2010–2022) for seven common cancers.
• Analysis distinguishes between organized screening, opportunistic detection, and symptom-driven diagnostic pathways.

Limitations

• The dataset is described in a 71.6 KB PDF; the underlying tabular data is not directly accessible.
• Column-level documentation is absent; field semantics must be inferred from the report.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Cancer in North America (CiNA) dataset.

Collection Method

Descriptive analysis comparing crude cancer rates before and after 2020.

Time Range

2010–2022

Freshness

Last updated 2026-05-22 12:59:23; freshness should be verified.

Geography

Canadian jurisdictions covered in the CiNA dataset.